These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37580082)

  • 1. Neuroprotective effects of hepatoma-derived growth factor in models of Huntington's disease.
    Voelkl K; Gutiérrez-Ángel S; Keeling S; Koyuncu S; da Silva Padilha M; Feigenbutz D; Arzberger T; Vilchez D; Klein R; Dudanova I
    Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37580082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
    Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
    Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
    Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
    Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
    Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
    Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
    J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.
    Díaz-Hernández M; Díez-Zaera M; Sánchez-Nogueiro J; Gómez-Villafuertes R; Canals JM; Alberch J; Miras-Portugal MT; Lucas JJ
    FASEB J; 2009 Jun; 23(6):1893-906. PubMed ID: 19171786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.